A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

This study is testing a drug called retatrutide — which targets multiple hormonal pathways including GLP-1, GIP, and glucagon — to understand how it affects insulin production and how well the body responds to insulin in people with type 2 diabetes. Retatrutide is in the same family as popular drugs like semaglutide (Ozempic) but adds additional targets. **You may be eligible if...** - You are an adult diagnosed with type 2 diabetes for at least 6 months - You are currently managing your diabetes with diet, exercise, and metformin (with or without other approved oral diabetes medications) - Your HbA1c (a 3-month blood sugar average) is between 6.5% and 9.5% - Your BMI is between 25 and 45 - Your body weight has been stable in the past 3 months **You may NOT be eligible if...** - You have type 1 diabetes - You are taking insulin or GLP-1 drugs (like semaglutide or liraglutide) - You have significant kidney, liver, or heart disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.